Monday, March 17, 2025 | 01:13 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Sun Pharma posts Rs 1,433-crore pre-tax profit in Q2, meets estimates

Sales or income from operations was Rs 7,949 crore, up 16 per cent year-on-year

Sun Pharma promoter meets Sebi chief to clarify on whistleblower complaint
Premium

Emerging market sales grew only 3 per cent to $201 million

Sohini Das Mumbai
Sun Pharmaceuticals on Thursday said that China and Japan are becoming increasingly important markets for growth. It posted its second quarter results, mostly in line with Street expectations, with pre-tax profit of Rs 1,433.38 crore, against Rs 111.94 crore last year, which was impacted by settlements related to an antitrust litigation concerning Modafinil in the US. 

Sun Pharma has been working on forging partnerships for China. On Wednesday, it announced a licensing agreement with AstraZeneca UK to introduce certain novel ready-to-use infusion oncology products in China. Speaking to analysts during the earnings call, Managing Director Dilip Shanghvi said: “The focus

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in